Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou, Harbin, Jinan, Jingjiang, Jingzhou, Lishui, Luoyang, Luoyang Shi, Nanchang, Nanjing, Shanghai, Shantou, Suzhou, Wuhan, Xi'an, Xuzhou, and Zigong, ChinaSee the 29 sites
- Phase
- Phase 3
Where in China
- Beijing Pinggu District HospitalBeijing, ChinaTaking people
- Peking University People's HospitalBeijing, ChinaTaking people
- Peking University Third HospitalBeijing, ChinaTaking people
- China-Japan Union HospitalChangchun, ChinaTaking people
- Changde First People's HospitalChangde, ChinaTaking people
- Changzhou Second People's HospitalChangzhou, ChinaTaking people
- Sichuan Provincial People's HospitalChengdu, ChinaTaking people
- 2nd Affiliated Hospital Chongqing Medical UniversityChongqing, ChinaTaking people
- Dalian Municipal Central Hospital Affiliated of Dalian Medical UniversityDalian, ChinaTaking people
- Guangdong Provincial People's HospitalGuangzhou, ChinaTaking people
- Zhujiang HospitalGuangzhou, ChinaTaking people
- Zhejiang Provincial People's HospitalHangzhou, ChinaTaking people
- The First Hospital of Harbin Medical UniversityHarbin, ChinaTaking people
- Jinan Central HospitalJinan, ChinaTaking people
- Jingjiang People's HospitalJingjiang, ChinaTaking people
- Jingzhou Central HospitalJingzhou, ChinaTaking people
- Lishui Central HospitalLishui, ChinaTaking people
- The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang, ChinaTaking people
- The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang Shi, ChinaTaking people
- The Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaNot yet recruiting
- Nanjing First HospitalNanjing, ChinaTaking people
- Jiading District Central HospitalShanghai, ChinaTaking people
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
- The Second Affiliated Hospital Of Shantou University Medical CollegeShantou, ChinaTaking people
- The Second Affiliated Hospital of Soochow UniversitySuzhou, ChinaTaking people
- Renmin Hospital of Wuhan UniversityWuhan, ChinaTaking people
- Shaanxi provincial people's hospitalXi'an, ChinaTaking people
- The Affiliated Hospital of Xuzhou Medical CollegeXuzhou, ChinaTaking people
- Zigong First People's HospitalZigong, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.